CY2008006I2 - Παραγωγα τροπανιου χρησιμα στη θεραπευτικη - Google Patents

Παραγωγα τροπανιου χρησιμα στη θεραπευτικη

Info

Publication number
CY2008006I2
CY2008006I2 CY200800006C CY2008006C CY2008006I2 CY 2008006 I2 CY2008006 I2 CY 2008006I2 CY 200800006 C CY200800006 C CY 200800006C CY 2008006 C CY2008006 C CY 2008006C CY 2008006 I2 CY2008006 I2 CY 2008006I2
Authority
CY
Cyprus
Prior art keywords
therapeutics
derivatives useful
tropane derivatives
tropane
useful
Prior art date
Application number
CY200800006C
Other languages
English (en)
Other versions
CY2008006I1 (el
Original Assignee
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer Limited filed Critical Pfizer Limited
Publication of CY2008006I1 publication Critical patent/CY2008006I1/el
Publication of CY2008006I2 publication Critical patent/CY2008006I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
CY200800006C 2000-05-26 2008-03-17 Παραγωγα τροπανιου χρησιμα στη θεραπευτικη CY2008006I2 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy
PCT/IB2001/000806 WO2001090106A2 (en) 2000-05-26 2001-05-09 Tryasolyl tropane derivatives as ccr5 modulators

Publications (2)

Publication Number Publication Date
CY2008006I1 CY2008006I1 (el) 2009-11-04
CY2008006I2 true CY2008006I2 (el) 2009-11-04

Family

ID=26244452

Family Applications (2)

Application Number Title Priority Date Filing Date
CY200800006C CY2008006I2 (el) 2000-05-26 2008-03-17 Παραγωγα τροπανιου χρησιμα στη θεραπευτικη
CY081101203T CY1108451T1 (el) 2000-05-26 2008-10-24 Παραγωγα τριαζολυλοτροπανιου ως ρυθμιστες ccr5

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY081101203T CY1108451T1 (el) 2000-05-26 2008-10-24 Παραγωγα τριαζολυλοτροπανιου ως ρυθμιστες ccr5

Country Status (51)

Country Link
EP (3) EP1990341B1 (el)
JP (2) JP3693957B2 (el)
KR (2) KR100523501B1 (el)
CN (2) CN1279040C (el)
AP (1) AP1965A (el)
AR (2) AR028622A1 (el)
AT (2) ATE260914T1 (el)
AU (2) AU5248201A (el)
BG (1) BG65966B1 (el)
BR (1) BRPI0110955B8 (el)
CA (1) CA2408909C (el)
CR (1) CR10145A (el)
CU (1) CU23288B7 (el)
CY (2) CY2008006I2 (el)
CZ (1) CZ299102B6 (el)
DE (3) DE60135685D1 (el)
DK (2) DK1284974T3 (el)
DZ (1) DZ3464A1 (el)
EA (2) EA005382B1 (el)
EE (1) EE05110B1 (el)
EG (1) EG24137A (el)
ES (3) ES2215129T3 (el)
FR (1) FR08C0007I2 (el)
GE (1) GEP20063799B (el)
HK (3) HK1054927A1 (el)
HR (1) HRP20020938B1 (el)
HU (1) HU225810B1 (el)
IL (2) IL152531A0 (el)
IS (1) IS2511B (el)
LT (1) LTC1284974I2 (el)
LU (1) LU91417I2 (el)
MA (1) MA26902A1 (el)
ME (1) ME00555B (el)
MX (1) MXPA02011631A (el)
MY (3) MY153023A (el)
NL (1) NL300338I2 (el)
NO (3) NO327892B1 (el)
NZ (1) NZ521477A (el)
OA (1) OA12264A (el)
PA (1) PA8517101A1 (el)
PE (1) PE20011371A1 (el)
PL (1) PL200551B1 (el)
PT (2) PT1526134E (el)
RS (2) RS51436B (el)
SI (2) SI1284974T1 (el)
SK (1) SK286129B6 (el)
TN (1) TNSN01077A1 (el)
TR (1) TR200400541T4 (el)
TW (1) TWI230160B (el)
UY (1) UY26727A1 (el)
WO (1) WO2001090106A2 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2215129T3 (es) * 2000-05-26 2004-10-01 Pfizer Inc. Derivados de triazolil tropano como modulares de ccr5.
CA2450271A1 (en) * 2001-06-12 2002-12-19 Sk Corporation Novel phenylalkyl diamine and amide analogs
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
ES2263960T3 (es) * 2002-04-08 2006-12-16 Pfizer Inc. Derivados de tropano como moduladores de ccr5.
AU2003230129A1 (en) * 2002-05-23 2003-12-12 Pfizer Inc. Method for identification of a ligand whereby receptor residence time is measured
EP1569647B1 (en) * 2002-12-13 2008-08-20 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
BRPI0413330A (pt) 2003-08-29 2006-10-10 Ranbaxy Lab Ltd inibidores de fosfodiesterase do tipo iv, composição farmacêutica contendo os mesmos e processo para sua preparação
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
CA2540834C (en) * 2003-10-03 2010-06-22 Pfizer Inc. Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
WO2005121145A2 (en) 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds
WO2006055660A2 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
KR20080035653A (ko) 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
AU2006303368B2 (en) 2005-10-19 2011-05-26 F. Hoffmann-La Roche Ag Non-Nucleoside Reverse Transcriptase Inhibitors
CN101501002B (zh) 2006-08-16 2012-06-27 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
BRPI0720436A2 (pt) 2006-12-13 2014-01-07 Hoffmann La Roche Inibidores de transcriptase reversa de não-nucleosídeo
US20080146605A1 (en) * 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
CA2716838C (en) * 2008-02-29 2014-01-07 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
WO2011011652A1 (en) * 2009-07-24 2011-01-27 Glaxosmithkline Llc Therapeutic compounds
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
PE20130529A1 (es) 2010-04-02 2013-05-14 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技（上海）有限公司 4，4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
EP0756596B1 (en) * 1994-04-19 2002-08-21 Neurosearch A/S Tropane-2-aldoxime derivatives as neurotransmitter reuptake inhibitors
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
WO1998002151A2 (en) * 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU5604998A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU8576098A (en) * 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
EP1047675A1 (en) * 1998-01-21 2000-11-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
ES2215129T3 (es) * 2000-05-26 2004-10-01 Pfizer Inc. Derivados de triazolil tropano como modulares de ccr5.

Also Published As

Publication number Publication date
ATE407134T1 (de) 2008-09-15
EP1526134A3 (en) 2006-11-29
JP2005194283A (ja) 2005-07-21
AR060159A2 (es) 2008-05-28
ES2215129T3 (es) 2004-10-01
TNSN01077A1 (fr) 2005-11-10
KR100523501B1 (ko) 2005-10-25
EA007580B1 (ru) 2006-12-29
WO2001090106A3 (en) 2002-03-28
PL200551B1 (pl) 2009-01-30
JP3693957B2 (ja) 2005-09-14
CN1680371A (zh) 2005-10-12
EP1526134B1 (en) 2008-09-03
WO2001090106A2 (en) 2001-11-29
HK1054927A1 (en) 2003-12-19
EP1990341A1 (en) 2008-11-12
PL359267A1 (en) 2004-08-23
DE60102233T2 (de) 2005-01-27
KR100548854B1 (ko) 2006-02-02
PA8517101A1 (es) 2002-10-24
ME00555A (en) 2011-12-20
EP1526134A2 (en) 2005-04-27
NO2010007I1 (no) 2010-04-08
EP1284974A2 (en) 2003-02-26
SI1526134T1 (sl) 2008-12-31
PT1284974E (pt) 2004-06-30
RS20090438A (en) 2010-05-07
NL300338I1 (nl) 2008-05-01
AU5248201A (en) 2001-12-03
TWI230160B (en) 2005-04-01
NL300338I2 (nl) 2008-06-02
IL152531A (en) 2010-05-17
EE05110B1 (et) 2008-12-15
ME00555B (me) 2011-12-20
NZ521477A (en) 2004-07-30
CR10145A (es) 2008-08-19
EP1284974B1 (en) 2004-03-03
RS50904B (sr) 2010-08-31
NO2020019I1 (no) 2020-06-30
DK1284974T3 (da) 2004-06-07
IL152531A0 (en) 2003-05-29
AU2001252482B2 (en) 2006-01-19
MXPA02011631A (es) 2003-03-27
CU23288B7 (es) 2008-06-30
UY26727A1 (es) 2001-12-28
CY2008006I1 (el) 2009-11-04
HUP0302474A2 (hu) 2003-11-28
CN1279040C (zh) 2006-10-11
EP1990341B1 (en) 2013-01-23
BR0110955A (pt) 2003-06-03
SK286129B6 (sk) 2008-04-07
LTPA2008004I1 (lt) 2020-07-27
BRPI0110955B1 (pt) 2016-06-28
LTC1284974I2 (lt) 2020-11-10
SK16432002A3 (sk) 2004-01-08
YU82202A (sh) 2005-11-28
BG65966B1 (bg) 2010-07-30
LU91417I9 (el) 2019-01-02
EE200200656A (et) 2004-06-15
CZ20023806A3 (cs) 2004-01-14
KR20030004417A (ko) 2003-01-14
LU91417I2 (fr) 2008-04-22
TR200400541T4 (tr) 2004-04-21
AU2001252482C1 (en) 2001-12-03
EA200401056A1 (ru) 2005-04-28
CA2408909A1 (en) 2001-11-29
ES2311126T3 (es) 2009-02-01
CN100355753C (zh) 2007-12-19
JP2003534343A (ja) 2003-11-18
IS6565A (is) 2002-09-24
HRP20020938B1 (en) 2011-05-31
CA2408909C (en) 2006-06-27
CY1108451T1 (el) 2014-04-09
ES2401812T3 (es) 2013-04-24
NO2010007I2 (no) 2013-09-09
DE60102233D1 (de) 2004-04-08
MY156920A (en) 2016-04-15
NO20025227L (no) 2002-10-31
FR08C0007I1 (el) 2008-04-25
BRPI0110955B8 (pt) 2021-05-25
EG24137A (en) 2008-08-06
DE122008000011I1 (de) 2008-06-05
IS2511B (is) 2009-05-15
HUP0302474A3 (en) 2007-05-29
FR08C0007I2 (fr) 2009-01-15
MY153023A (en) 2014-12-31
EA005382B1 (ru) 2005-02-24
ATE260914T1 (de) 2004-03-15
JP4854970B2 (ja) 2012-01-18
GEP20063799B (en) 2006-04-25
AP2002002663A0 (en) 2002-12-31
CZ299102B6 (cs) 2008-04-23
MY131019A (en) 2007-07-31
PE20011371A1 (es) 2002-01-18
DZ3464A1 (el) 2001-11-29
NO20025227D0 (no) 2002-10-31
HRP20020938A2 (en) 2005-02-28
HK1078573A1 (en) 2006-03-17
EA200201141A1 (ru) 2003-04-24
AP1965A (en) 2009-03-04
DK1526134T3 (da) 2008-11-17
OA12264A (en) 2003-11-10
BG107140A (bg) 2003-05-30
MA26902A1 (fr) 2004-12-20
RS51436B (en) 2011-04-30
HU225810B1 (en) 2007-10-29
KR20050046743A (ko) 2005-05-18
SI1284974T1 (en) 2004-08-31
NO327892B1 (no) 2009-10-12
CN1437599A (zh) 2003-08-20
DE60135685D1 (de) 2008-10-16
HK1090836A1 (en) 2007-01-05
AR028622A1 (es) 2003-05-14
PT1526134E (pt) 2008-10-28

Similar Documents

Publication Publication Date Title
CY2008006I2 (el) Παραγωγα τροπανιου χρησιμα στη θεραπευτικη
DE60119492D1 (de) Purinderivate
DE60103537D1 (de) Purinderivate
DK1341791T3 (da) Thioethersubstituerede imidazoquinoliner
ID30366A (id) Pakaian dalam sekali pakai
NO20024766L (no) Etylendiaminderivater
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
ID25435A (id) Pakaian dalam sekali pakai
ATE447004T1 (de) Zusammensetzungen in beuteln
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1280809T3 (da) Antitumorecteinascidinderivater
NO20023770D0 (no) Indol-3-ylderivater
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
ATE280752T1 (de) Aminomethyl-phenyl-cyclohexanonderivate
DE60015576D1 (de) 4-fluoroalkyl-3-halophenyl nortropane
GB0019234D0 (en) Therapeutics
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no) 2-fenylpyran-4-on-derivater
DE50002735D1 (de) Sesselmechanik
FI20000174A0 (fi) Sulkusäkki
DE50104434D1 (de) Lactam-substituierte pyrazolopyridinderivate
PT1043026E (pt) Terapeutica do melanoma
DK1217978T3 (da) Absorberende struktur i en absorberende artikel
ITSS20000006V0 (it) Portacenere antivento